CERT Quote, Financials, Valuation and Earnings

DarioHealth Corp. has a net margin of 1.46% compared to Certara, Inc.'s net margin of -41.48%. Certara, Inc.'s return on equity of 1.02% beat DarioHealth Corp.'s return on equity of -41.55%.

Certara, Inc. has a consensus price target of $13.21, signalling upside risk potential of 36.45%. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 54.01%. Given that DarioHealth Corp. has higher upside potential than Certara, Inc., analysts believe DarioHealth Corp. is more attractive than Certara, Inc..

Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.716%.

Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Certara, Inc. pays -- of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend.

Certara, Inc. quarterly revenues are $104.6M, which are larger than DarioHealth Corp. quarterly revenues of $5M. Certara, Inc.'s net income of $1.5M is higher than DarioHealth Corp.'s net income of -$2.1M. Notably, Certara, Inc.'s price-to-earnings ratio is 143.41x while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.75x versus 6.58x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of 1.46% compared to Certara, Inc.'s net margin of 11.54%. Certara, Inc.'s return on equity of 1.02% beat National Research Corp.'s return on equity of 61.55%.

Certara, Inc. has a consensus price target of $13.21, signalling upside risk potential of 36.45%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Certara, Inc. has higher upside potential than National Research Corp., analysts believe Certara, Inc. is more attractive than National Research Corp..

Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 2.97% to investors and pays a quarterly dividend of $0.12 per share. Certara, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Certara, Inc. quarterly revenues are $104.6M, which are larger than National Research Corp. quarterly revenues of $34.6M. Certara, Inc.'s net income of $1.5M is lower than National Research Corp.'s net income of $4M. Notably, Certara, Inc.'s price-to-earnings ratio is 143.41x while National Research Corp.'s PE ratio is 22.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.75x versus 2.65x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of 1.46% compared to Certara, Inc.'s net margin of -2156852.78%. Certara, Inc.'s return on equity of 1.02% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

Certara, Inc. has a consensus price target of $13.21, signalling upside risk potential of 36.45%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 716.7%. Given that Predictive Oncology, Inc. has higher upside potential than Certara, Inc., analysts believe Predictive Oncology, Inc. is more attractive than Certara, Inc..

Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Certara, Inc. pays -- of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend.

Certara, Inc. quarterly revenues are $104.6M, which are larger than Predictive Oncology, Inc. quarterly revenues of $3.6K. Certara, Inc.'s net income of $1.5M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, Certara, Inc.'s price-to-earnings ratio is 143.41x while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.75x versus 16.89x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of 1.46% compared to Certara, Inc.'s net margin of 9.46%. Certara, Inc.'s return on equity of 1.02% beat Spok Holdings, Inc.'s return on equity of 10.88%.

Certara, Inc. has a consensus price target of $13.21, signalling upside risk potential of 36.45%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 60.06%. Given that Spok Holdings, Inc. has higher upside potential than Certara, Inc., analysts believe Spok Holdings, Inc. is more attractive than Certara, Inc..

Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.53% to investors and pays a quarterly dividend of $0.31 per share. Certara, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

Certara, Inc. quarterly revenues are $104.6M, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. Certara, Inc.'s net income of $1.5M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, Certara, Inc.'s price-to-earnings ratio is 143.41x while Spok Holdings, Inc.'s PE ratio is 16.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.75x versus 1.95x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.